Table 4.
Association of CD4+ T-cell counts with cytopenia in HIV-positive individuals at Madda Walabu University Goba Referral Hospital, southeast Ethiopia, 1 April to 30 June 2018 (n = 308).
| Hematological abnormalities | CD4 counts (cells/µL) before HAART | Hematological abnormalities | CD4 counts (cells/µL) after HAART | ||||||
|---|---|---|---|---|---|---|---|---|---|
| <200 | 200–500 | ˃500 | p-value | <200 | 200–500 | ˃500 | p-value | ||
| Anemia | 50 (47.2%) | 35 (28%) | 13 (16.9%) | 0.001* | Anemia | 4 (9.3%) | 19 (17.6%) | 22 (13.9%) | 0.783 |
| Leukopenia | 25 (23.6%) | 28 (22.4%) | 3 (3.9%) | 0.001* | Leukopenia | 9 (20.9%) | 19 (17.8%) | 46 (29.3%) | 0.176 |
| Lymphopenia | 2 (1.9%) | 6 (4.8%) | 1 (1.3%) | 0.263 | Lymphopenia | 1 (2.3%) | 3 (2.8%) | 7 (4.5%) | 0.785 |
| Neutropenia | 21 (19.8%) | 24 (19.2%) | 3 (3.9%) | 0.005* | Neutropenia | 6 (14%) | 18 (16.7%) | 31 (19.7%) | 0.274 |
| Thrombocytopenia | 15 (14.2%) | 14 (11.2%) | 6 (7.8%) | 0.772 | Thrombocytopenia | 3 (7%) | 4 (3.7%) | 7 (4.5%) | 0.346 |
CD: cluster of differentiation; HAART: highly active antiretroviral therapy.
*
Level of significance (p < 0.05).